IP Library Granted Patent US 9,862,680
Granted Patent B2
US 9,862,680 · App. 15/181,303 · Granted Jan 9, 2018

Peripherally substituted monocyclic beta-lactams

Inventors: Marvin Miller (South Bend, IN); Serena Carosso (Mishawaka, IN)
Assignee: University of Notre Dame du Lac
C07D205/08C07D417/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,862,680
App. No.
15/181,303
Granted
Jan 9, 2018
Kind
B2
Abstract

The invention provides monobactams that can be used as antibacterial agents or intermediates for the preparation of other useful compounds such as antibacterial agents.

Claims (21)

1. An N-sulfonyloxy β-lactam compound of Formula (I):

wherein R is an optionally substituted aryl with the proviso that R is not tolyl, or an optionally substituted alkenyl(aryl), and the bromine is optionally replaced by a sulfur-containing side chain; and Formula (I) has an optional aminothiazole methoxime (ATMO) containing side chain at C3.

2. The compound of claim 1 wherein R is selected from the group consisting of:

3. A compound selected from the group consisting of 41, 43, 44, and 48, or a pharmaceutically acceptable salt thereof:

4. The compound of claim 1 wherein the bromine moiety of Formula (I) is replaced with a sulfur-containing side chain.

5. The compound of claim 1 wherein Formula (I) has an aminothiazole methoxime (ATMO) containing side chain at the C3 position.

6. A method of inhibiting β-lactamase activity comprising contacting a β-lactamase enzyme with a compound of claim 1 .

7. The method of claim 6 , wherein the β-lactamase enzyme is a β-lactamase enzyme isolated from a pathogenic bacterium.

8. The method of claim 6 , wherein the β-lactamase enzyme is naturally occurring in a pathogenic bacterium.

9. The method of claim 8 , wherein the pathogenic bacterium is selected from the group consisting of gram positive bacteria and gram negative bacteria.

10. A method of inhibiting β-lactamase activity comprising contacting an N-sulfonyloxy β-lactam of claim 1 with a β-lactamase enzyme that is naturally occurring in a pathogenic bacterium selected from the group consisting of gram positive bacteria and gram negative bacteria, wherein the gram positive bacteria are selected from the group consisting of B. subtilis and M. vaccae.

11. The method of claim 9 , wherein the gram negative bacteria are selected from the group consisting of A. baumannii, P. aeruginosa and E. coli.

12. A method of inhibiting β-lactamase activity comprising contacting a β-lactamase enzyme with a compound of claim 2 .

13. A method of treating a bacterial infection comprising administering to a subject in need thereof an effective antibacterial amount of a compound of claim 3 , or a pharmaceutically acceptable salt thereof.

14. A method of treating a bacterial infection comprising administering to a subject in need thereof an effective antibacterial amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

15. A method of treating a bacterial infection comprising administering to a subject in need thereof an effective antibacterial amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof.

16. A method of treating a bacterial infection comprising administering to a subject in need thereof an effective antibacterial amount of a compound of claim 4 , or a pharmaceutically acceptable salt thereof.

17. A method of treating a bacterial infection comprising administering to a subject in need thereof an effective antibacterial amount of a compound of claim 5 , or a pharmaceutically acceptable salt thereof.

18. A method of inhibiting β-lactamase activity comprising contacting a β-lactamase enzyme with a compound of claim 3 .

19. A method of inhibiting β-lactamase activity comprising contacting a β-lactamase enzyme with a compound of claim 4 .

20. A method of inhibiting β-lactamase activity comprising contacting a β-lactamase enzyme with a compound of claim 5 .

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 27, 2018
From: UNIVERSITY OF NOTRE DAME
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046034/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2016
From: MILLER, MARVIN; CAROSSO, SERENA
To: THE UNIVERSITY OF NOTRE DAME DU LAC
Reel/Frame 040434/0987 →
Continuity (1)
Related Publication 20170355671A1 · Dec 14, 2017